PortalPublikationenGrowing experience with mTOR inhibitors in pediatric solid o...

Growing experience with mTOR inhibitors in pediatric solid organ transplantation

Standard

Growing experience with mTOR inhibitors in pediatric solid organ transplantation. / Ganschow, R; Pape, L; Sturm, E; Bauer, J; Melter, M; Gerner, P; Hoecker, B; Ahlenstiel, T; Kemper, M; Brinkert, F; Sachse, M M; Tönshoff, B.

in: PEDIATR TRANSPLANT, Jahrgang 17, Nr. 7, 01.11.2013, S. 694-706.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Ganschow, R, Pape, L, Sturm, E, Bauer, J, Melter, M, Gerner, P, Hoecker, B, Ahlenstiel, T, Kemper, M, Brinkert, F, Sachse, MM & Tönshoff, B 2013, 'Growing experience with mTOR inhibitors in pediatric solid organ transplantation', PEDIATR TRANSPLANT, Jg. 17, Nr. 7, S. 694-706. https://doi.org/10.1111/petr.12147

APA

Ganschow, R., Pape, L., Sturm, E., Bauer, J., Melter, M., Gerner, P., Hoecker, B., Ahlenstiel, T., Kemper, M., Brinkert, F., Sachse, M. M., & Tönshoff, B. (2013). Growing experience with mTOR inhibitors in pediatric solid organ transplantation. PEDIATR TRANSPLANT, 17(7), 694-706. https://doi.org/10.1111/petr.12147

Vancouver

Ganschow R, Pape L, Sturm E, Bauer J, Melter M, Gerner P et al. Growing experience with mTOR inhibitors in pediatric solid organ transplantation. PEDIATR TRANSPLANT. 2013 Nov 1;17(7):694-706. https://doi.org/10.1111/petr.12147

Bibtex

@article{9f1792457d094eeab4322bf2cbbb2a3e,
title = "Growing experience with mTOR inhibitors in pediatric solid organ transplantation",
abstract = "Controlled trials of mTOR inhibitors in children following solid organ transplantation are scarce, although evidence from prospective single-arm studies is growing. Everolimus with reduced CNI therapy has been shown to be efficacious and safe in de novo pediatric kidney transplant patients in prospective trials. Prospective and retrospective data in children converted from CNI therapy to mTOR inhibition following kidney, liver, or heart transplantation suggest preservation of immunosuppressive efficacy. Good renal function has been maintained when mTOR inhibitors are used de novo in children following kidney transplantation or after conversion to mTOR inhibition with CNI minimization. mTOR inhibition with reduced CNI exposure is associated with a low risk for developing infection in children. Growth and development do not appear to be impaired during low-dose mTOR inhibition, but more studies are required. No firm conclusions can be drawn as to whether mTOR inhibitors should be discontinued in children requiring surgical intervention or whether mTOR inhibition delays progression of hepatic fibrosis after pediatric liver transplantation. In conclusion, current evidence suggests that use of mTOR inhibitors in children undergoing solid organ transplantation is efficacious and safe, but a number of issues remain unresolved and further studies are required.",
keywords = "Calcineurin, Child, Fibrosis, Heart Transplantation, Humans, Immunosuppressive Agents, Kidney Transplantation, Liver, Liver Transplantation, Lymphoproliferative Disorders, Postoperative Complications, Risk, Sirolimus, TOR Serine-Threonine Kinases, Treatment Outcome, Wound Healing",
author = "R Ganschow and L Pape and E Sturm and J Bauer and M Melter and P Gerner and B Hoecker and T Ahlenstiel and M Kemper and F Brinkert and Sachse, {M M} and B T{\"o}nshoff",
note = "{\textcopyright} 2013 John Wiley & Sons A/S.",
year = "2013",
month = nov,
day = "1",
doi = "10.1111/petr.12147",
language = "English",
volume = "17",
pages = "694--706",
journal = "PEDIATR TRANSPLANT",
issn = "1397-3142",
publisher = "Wiley-Blackwell",
number = "7",

}

RIS

TY - JOUR

T1 - Growing experience with mTOR inhibitors in pediatric solid organ transplantation

AU - Ganschow, R

AU - Pape, L

AU - Sturm, E

AU - Bauer, J

AU - Melter, M

AU - Gerner, P

AU - Hoecker, B

AU - Ahlenstiel, T

AU - Kemper, M

AU - Brinkert, F

AU - Sachse, M M

AU - Tönshoff, B

N1 - © 2013 John Wiley & Sons A/S.

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Controlled trials of mTOR inhibitors in children following solid organ transplantation are scarce, although evidence from prospective single-arm studies is growing. Everolimus with reduced CNI therapy has been shown to be efficacious and safe in de novo pediatric kidney transplant patients in prospective trials. Prospective and retrospective data in children converted from CNI therapy to mTOR inhibition following kidney, liver, or heart transplantation suggest preservation of immunosuppressive efficacy. Good renal function has been maintained when mTOR inhibitors are used de novo in children following kidney transplantation or after conversion to mTOR inhibition with CNI minimization. mTOR inhibition with reduced CNI exposure is associated with a low risk for developing infection in children. Growth and development do not appear to be impaired during low-dose mTOR inhibition, but more studies are required. No firm conclusions can be drawn as to whether mTOR inhibitors should be discontinued in children requiring surgical intervention or whether mTOR inhibition delays progression of hepatic fibrosis after pediatric liver transplantation. In conclusion, current evidence suggests that use of mTOR inhibitors in children undergoing solid organ transplantation is efficacious and safe, but a number of issues remain unresolved and further studies are required.

AB - Controlled trials of mTOR inhibitors in children following solid organ transplantation are scarce, although evidence from prospective single-arm studies is growing. Everolimus with reduced CNI therapy has been shown to be efficacious and safe in de novo pediatric kidney transplant patients in prospective trials. Prospective and retrospective data in children converted from CNI therapy to mTOR inhibition following kidney, liver, or heart transplantation suggest preservation of immunosuppressive efficacy. Good renal function has been maintained when mTOR inhibitors are used de novo in children following kidney transplantation or after conversion to mTOR inhibition with CNI minimization. mTOR inhibition with reduced CNI exposure is associated with a low risk for developing infection in children. Growth and development do not appear to be impaired during low-dose mTOR inhibition, but more studies are required. No firm conclusions can be drawn as to whether mTOR inhibitors should be discontinued in children requiring surgical intervention or whether mTOR inhibition delays progression of hepatic fibrosis after pediatric liver transplantation. In conclusion, current evidence suggests that use of mTOR inhibitors in children undergoing solid organ transplantation is efficacious and safe, but a number of issues remain unresolved and further studies are required.

KW - Calcineurin

KW - Child

KW - Fibrosis

KW - Heart Transplantation

KW - Humans

KW - Immunosuppressive Agents

KW - Kidney Transplantation

KW - Liver

KW - Liver Transplantation

KW - Lymphoproliferative Disorders

KW - Postoperative Complications

KW - Risk

KW - Sirolimus

KW - TOR Serine-Threonine Kinases

KW - Treatment Outcome

KW - Wound Healing

U2 - 10.1111/petr.12147

DO - 10.1111/petr.12147

M3 - SCORING: Journal article

C2 - 24004351

VL - 17

SP - 694

EP - 706

JO - PEDIATR TRANSPLANT

JF - PEDIATR TRANSPLANT

SN - 1397-3142

IS - 7

ER -